Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Integra Lifesciences Holdings Corp. (IART)
NASDAQ:IART
Integra Lifesciences (IART) Stock Price & Analysis
209 Followers
IART Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$31.57 - $59.11
Previous Close$31.82
Volume401.09K
Average Volume (3M)655.29K
Market Cap
$2.52B
Enterprise Value$3.92B
Total Cash (Recent Filing)$273.73M
Total Debt (Recent Filing)$1.69B
Price to Earnings (P/E)37.7
Beta1.06
Next Earnings
Apr 25, 2024EPS Estimate
$0.55Last Dividend Ex-Date
Jul 02, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)0.84
Shares Outstanding78,219,780
10 Day Avg. Volume583,576
30 Day Avg. Volume655,287
Standard Deviation0.10
R-Squared0.39
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-4.79
Price to Sales (P/S)1.61
Price to Cash Flow (P/CF)10.90
P/FCF Ratio9.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.54
Enterprise Value/Gross Profit4.04
Enterprise Value/Ebitda13.57
Forecast
1Y Price Target
$43.50Price Target Upside36.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Integra Lifesciences News
Bulls Say, Bears Say
Bulls Say
Financial OutlookCompany's Long Range Plan calls for significant revenue and double-digit adjusted EPS growth.
Product LaunchThe relaunch of Boston is on track, which could provide a revenue boost in the second half of the year.
Regulatory ApprovalCereLink received 510(k) approval, positioning the company for a successful product relaunch.
Bears Say
Corporate LeadershipThe CEO's retirement is due to personal reasons, which introduces uncertainty around leadership transition.
Financial PerformanceRevenue and adjusted EPS fell below consensus estimates, indicating potential financial weaknesses.
Product IssuesIART initiated a voluntary global recall of CereLink intracranial pressure monitors in August, 2022.
---
Ownership Overview
28.26% Insiders
39.92% Mutual Funds
20.92% Other Institutional Investors
10.90% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IART FAQ
What was Integra Lifesciences Holdings Corp.’s price range in the past 12 months?
Integra Lifesciences Holdings Corp. lowest stock price was $31.57 and its highest was $59.11 in the past 12 months.
What is Integra Lifesciences Holdings Corp.’s market cap?
Currently, no data Available
When is Integra Lifesciences Holdings Corp.’s upcoming earnings report date?
Integra Lifesciences Holdings Corp.’s upcoming earnings report date is Apr 25, 2024 which is in 8 days.
How were Integra Lifesciences Holdings Corp.’s earnings last quarter?
Integra Lifesciences Holdings Corp. released its earnings results on Feb 28, 2024. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.903 by -$0.013.
Is Integra Lifesciences Holdings Corp. overvalued?
According to Wall Street analysts Integra Lifesciences Holdings Corp.’s price is currently Undervalued.
Does Integra Lifesciences Holdings Corp. pay dividends?
Integra Lifesciences Holdings Corp. pays a Notavailable dividend of $3.18 which represents an annual dividend yield of N/A. See more information on Integra Lifesciences Holdings Corp. dividends here
What is Integra Lifesciences Holdings Corp.’s EPS estimate?
Integra Lifesciences Holdings Corp.’s EPS estimate is $0.55.
How many shares outstanding does Integra Lifesciences Holdings Corp. have?
Integra Lifesciences Holdings Corp. has 78,219,780 shares outstanding.
What happened to Integra Lifesciences Holdings Corp.’s price movement after its last earnings report?
Integra Lifesciences Holdings Corp. reported an EPS of $0.89 in its last earnings report, missing expectations of $0.903. Following the earnings report the stock price went down -12.65%.
Which hedge fund is a major shareholder of Integra Lifesciences Holdings Corp.?
Among the largest hedge funds holding Integra Lifesciences Holdings Corp.’s share is Deerfield Management Company, LP. It holds Integra Lifesciences Holdings Corp.’s shares valued at 49M.
---
Integra Lifesciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.50 (36.15% Upside)
$43.50 (36.15% Upside)
Hedge Fund Trend
Decreased
By 92.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.04%
12-Months-Change
Fundamentals
Return on Equity
3.99%
Trailing 12-Months
Asset Growth
-2.77%
Trailing 12-Months
Company Description
Integra Lifesciences Holdings Corp.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.
---
IART Company Deck
---
IART Earnings Call
Q4 2024
0:00 / 0:00
---
IART Stock 12 Months Forecast
Average Price Target
$43.50
▲(36.15% Upside)
Technical Analysis
Best Analysts Covering IART
1 Year
1 Year Success Rate
43/59 ratings generated profit
1 Year Average Return
+14.19%
reiterated a buy rating 9 months ago
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 72.88% of your transactions generating a profit, with an average return of +14.19% per trade.
---